NASDAQ:UTHR United Therapeutics (UTHR) Stock Price, News & Analysis $328.40 +2.58 (+0.79%) Closing price 06/9/2025 04:00 PM EasternExtended Trading$328.60 +0.20 (+0.06%) As of 06/9/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About United Therapeutics Stock (NASDAQ:UTHR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get United Therapeutics alerts:Sign Up Key Stats Today's Range$323.53▼$329.8550-Day Range$278.89▼$328.4052-Week Range$266.98▼$417.82Volume541,269 shsAverage Volume439,644 shsMarket Capitalization$14.81 billionP/E Ratio14.42Dividend YieldN/APrice Target$393.00Consensus RatingModerate Buy Company OverviewUnited Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Read More… United Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks97th Percentile Overall ScoreUTHR MarketRank™: United Therapeutics scored higher than 97% of companies evaluated by MarketBeat, and ranked 63rd out of 1,886 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageUnited Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about United Therapeutics' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth12.30% Earnings GrowthEarnings for United Therapeutics are expected to grow by 12.30% in the coming year, from $24.48 to $27.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 14.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.68.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 14.42, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.17.Price to Earnings Growth RatioUnited Therapeutics has a PEG Ratio of 0.97. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about United Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.77% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in United Therapeutics has recently increased by 6.60%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-2.00 Percentage of Shares Shorted4.77% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in United Therapeutics has recently increased by 6.60%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment1.05 News SentimentUnited Therapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for United Therapeutics this week, compared to 14 articles on an average week.Search InterestOnly 1 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,923,950.00 in company stock.Percentage Held by Insiders10.30% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about United Therapeutics' insider trading history. Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address UTHR Stock News HeadlinesLeerink Partnrs Issues Optimistic Outlook for UTHR EarningsJune 8 at 1:15 AM | americanbankingnews.comUnited Therapeutics: A Cheap But Complicated TaleJune 6, 2025 | seekingalpha.comThe Robotics Revolution has arrived … and one $7 stock could take off as a result.It could very well mark the beginning of a new multitrillion-dollar industrial revolution. Up until now, we've imagined robots doing things like cleaning our homes, serving drinks at restaurants, greeting guests in hotel lobbies, stacking shelves in warehouses, and so on. Very soon, there will be a robot that won't do any of that. However, it's impact on the US economy and society will be FAR greater than anything we ever imagined.June 10, 2025 | Weiss Ratings (Ad)Corcept (CORT) Down 1.7% Since Last Earnings Report: Can It Rebound?June 4, 2025 | finance.yahoo.comCantor Fitzgerald Initiates Coverage of United Therapeutics (UTHR) with Overweight RecommendationJune 2, 2025 | msn.comUnited Therapeutics (UTHR) Receives Overweight Rating from Cantor Fitzgerald | UTHR Stock NewsJune 2, 2025 | gurufocus.comUnited Therapeutics Co. (NASDAQ:UTHR) EVP Sells $3,476,770.00 in StockJune 2, 2025 | americanbankingnews.comAnalysts Set United Therapeutics Co. (NASDAQ:UTHR) PT at $392.00June 1, 2025 | americanbankingnews.comSee More Headlines UTHR Stock Analysis - Frequently Asked Questions How have UTHR shares performed this year? United Therapeutics' stock was trading at $352.84 at the start of the year. Since then, UTHR shares have decreased by 6.9% and is now trading at $328.40. View the best growth stocks for 2025 here. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) announced its quarterly earnings results on Wednesday, April, 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. The firm's quarterly revenue was up 17.2% on a year-over-year basis. Read the conference call transcript. Who are United Therapeutics' major shareholders? Top institutional investors of United Therapeutics include Vanguard Group Inc. (9.88%), Wellington Management Group LLP (4.49%), AQR Capital Management LLC (2.01%) and LSV Asset Management (2.00%). Insiders that own company stock include Paul A Mahon, Tommy G Thompson, James Edgemond, Judy D Olian, Nilda Mesa, Louis W Sullivan, Christopher Causey, Michael Benkowitz, Raymond Dwek, Martine A Rothblatt and Christopher Patusky. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that United Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings4/30/2025Today6/09/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:UTHR CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees980Year Founded1996Price Target and Rating Average Stock Price Target$393.00 High Stock Price Target$600.00 Low Stock Price Target$302.00 Potential Upside/Downside+19.7%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$25.06 Trailing P/E Ratio14.42 Forward P/E Ratio13.42 P/E Growth0.97Net Income$984.80 million Net Margins40.31% Pretax Margin52.17% Return on Equity19.22% Return on Assets16.15% Debt Debt-to-Equity RatioN/A Current Ratio4.58 Quick Ratio4.41 Sales & Book Value Annual Sales$2.99 billion Price / Sales4.95 Cash Flow$19.75 per share Price / Cash Flow16.63 Book Value$127.35 per share Price / Book2.58Miscellaneous Outstanding Shares45,107,000Free Float39,332,000Market Cap$14.81 billion OptionableOptionable Beta0.57 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:UTHR) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWall Street Legend: Crash coming in March—details hereBad News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history give...Chaikin Analytics | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredTrump’s treachery A few months ago, I released a list of six companies I believed were going to appreciate under Trump’s second ...Porter & Company | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.